🇺🇸 FDA

Intelligence · Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.

Programs
375

Quick answer

First People's Hospital has 375 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Aumolertinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  2. Autologous CD5 CAR T-cells

    The First People's Hospital of Lianyungang

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  3. Azacitidine

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome

    phase 2 small molecule completed

    1 trial

  4. Azacitidine (AZA) with Ruxolitinib

    The First People's Hospital of Lianyungang

    MDS/MPN

    phase 2 small molecule active

    1 trial

  5. Azacitidine Injection

    The First People's Hospital of Lianyungang

    B Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  6. Azacitidine in Combination With Venetoclax

    The First People's Hospital of Lianyungang

    Hematologic Malignancy

    phase 2 small molecule active

    1 trial

  7. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  8. BM-MSCs

    The First People's Hospital of Lianyungang

    Kidney Transplantation

    phase 2 other active

    2 trials

  9. Baritinib

    The First People's Hospital of Lianyungang

    Intracerebral Hemorrhage

    phase 2 small molecule completed

    1 trial

  10. Becotatug Vedotin

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  11. Bevacizumab

    The First People's Hospital of Lianyungang

    Malignant Pleural Effusion

    phase 2 small molecule active

    1 trial

  12. Bevacizumab

    The First People's Hospital of Lianyungang

    Lung, Carcinoma

    phase 2 small molecule active

    1 trial

  13. Bevacizumab

    The First People's Hospital of Lianyungang

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  14. Bevacizumab Biosimilar IBI305

    The First People's Hospital of Lianyungang

    Post-orthotopic Liver Transplantation

    phase 2 small molecule active

    1 trial

  15. Bevacizumab combined with Oxaliplatin and TAS-102

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  17. BinD19

    The First People's Hospital of Lianyungang

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  18. Blinatumomab

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  19. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  20. C225 (cetuximab)

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  21. CAR T-cell therapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  22. CAR-BCMA T Cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  23. CAR-T

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Chronic, B-Cell

    phase 2 mab active

    1 trial

  24. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  25. CAR-T treatment

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  26. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  27. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  28. CIK

    The First People's Hospital of Lianyungang

    Lung Adenocarcinoma

    phase 2 mab terminated

    1 trial

  29. CM313 (SC)

    The First People's Hospital of Lianyungang

    Pemphigus Disease

    phase 2 small molecule active

    1 trial

  30. CM336 Injection

    The First People's Hospital of Lianyungang

    Autoimmune Bullous Disease

    phase 2 mab active

    1 trial

  31. CMOP±R

    The First People's Hospital of Lianyungang

    NHL

    phase 2 small molecule active

    1 trial

  32. Cadonilimab

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  33. Cadonilimab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 2 small molecule active

    1 trial

  34. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  35. Camrelizumab

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 small molecule active

    1 trial

  36. Camrelizumab

    The First People's Hospital of Lianyungang

    Locally Advanced or Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  37. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  38. Camrelizumab

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  39. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  40. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  41. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  42. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  43. Cangpo Liujun Prescription

    The First People's Hospital of Lianyungang

    Cancer-Related Fatigue

    phase 2 small molecule active

    1 trial

  44. Capecitabine

    The First People's Hospital of Lianyungang

    Biliary Carcinoma

    phase 2 small molecule active

    1 trial

  45. Capecitabine-Oxaliplatin-Irinotecan Combination

    The First People's Hospital of Lianyungang

    Unresectable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  46. Chidamide

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 2 small molecule active

    2 trials

  47. Chidamide Combined with NKG2D CAR-NK Cell Therapy

    The First People's Hospital of Lianyungang

    HIV (Human Immunodeficiency Virus)

    phase 2 small molecule active

    1 trial

  48. Chidamide combined with Duvillisib

    The First People's Hospital of Lianyungang

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

375 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.